BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35895622)

  • 1. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
    Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
    J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
    Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
    Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study.
    van Houten VM; Leemans CR; Kummer JA; Dijkstra J; Kuik DJ; van den Brekel MW; Snow GB; Brakenhoff RH
    Clin Cancer Res; 2004 Jun; 10(11):3614-20. PubMed ID: 15173067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
    van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
    J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
    Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients.
    Dasgupta S; Koch R; Westra WH; Califano JA; Ha PK; Sidransky D; Koch WM
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1205-11. PubMed ID: 20660573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
    Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
    Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck.
    Brennan JA; Mao L; Hruban RH; Boyle JO; Eby YJ; Koch WM; Goodman SN; Sidransky D
    N Engl J Med; 1995 Feb; 332(7):429-35. PubMed ID: 7619114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
    Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
    Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas.
    Tan HK; Saulnier P; Auperin A; Lacroix L; Casiraghi O; Janot F; Fouret P; Temam S
    Br J Cancer; 2008 Jul; 99(2):357-63. PubMed ID: 18594522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
    Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
    Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
    Wu P; Xie C; Yang L; Liu Y; Zeng J; Li X; Fang X; Fan Y; Zhao S; Kuang N; Xuan T; Xia X; Yi X; Huang Y; Yu Z; Tang Y
    Br J Cancer; 2021 Sep; 125(6):854-864. PubMed ID: 34230611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.
    Patel KB; Padhya TA; Huang J; Hernandez-Prera JC; Li T; Chung CH; Wang L; Wang X
    Mol Carcinog; 2023 Apr; 62(4):493-502. PubMed ID: 36636912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Patients With Head and Neck Squamous Cell Carcinoma Can be Predicted by Expression of eIF4E and Osteopontin in Free Surgical Margins.
    Abouhashem NS; Elwan A; Elaidy NF
    Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):e40-e49. PubMed ID: 35285458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.